radioligand
Sign in to saveA radioligand is a microscopic particle which consists of a therapeutic radioactive isotope and the cell-targeting compound — the ligand. The ligand is the target binding site; it may be on the surface of the targeted cancer cell for therapeutic purposes. Radioisotopes can occur naturally or be synthesized and produced in a cyclotron/nuclear reactor. Types of radioisotopes include Y-90, H-3, C-11, Lu-177, Ac-225, Ra-223, In-111, I-131, and I-125. Thus, radioligands must be produced in special nuclear reactors for the radioisotope to remain stable. Radioligands can be used to analyze/characteri
In the Vinony graph
Vinony's link graph records 61 inbound references to radioligand, and connects out to alpha particle, isotope of lutetium and Marie Curie.
It sits within the topics Biochemistry detection methods, Biomolecules and Receptors.
Vinony links it to 8 Wikipedia language editions.
~23 min read
Encyclopedic overview
22 sectionsContents
- History
- Radioactive isotopes commonly used
- Ligands
- Use in drug delivery and release
- Use in imaging
- Binding assays
- Saturation binding
- Competition binding
- Kinetic binding
- Alpha and beta particles
- Oncological applications
- Lutathera for neuroendocrine tumors
- Pluvicto and Xofigo for prostate cancer
- Iodine-131 tositumomab (Bexxar) and Zevalin (90Y-ibritumomab tiuxetan) for non-Hodgkin's lymphoma
- Requirements for administration
- Patient eligibility
- Hospital requirements and staff training
- Limitations
- Future potential applications
- See also
- References
- Further reading
A radioligand is a microscopic particle which consists of a therapeutic radioactive isotope and the cell-targeting compound — the ligand. The ligand is the target binding site; it may be on the surface of the targeted cancer cell for therapeutic purposes. Radioisotopes can occur naturally or be synthesized and produced in a cyclotron/nuclear reactor. Types of radioisotopes include Y-90, H-3, C-11, Lu-177, Ac-225, Ra-223, In-111, I-131, and I-125. Thus, radioligands must be produced in special nuclear reactors for the radioisotope to remain stable. Radioligands can be used to analyze/characterize receptors, to perform binding assays, to help in diagnostic imaging, and to provide targeted cancer therapy. Radiation is a novel method of treating cancer and is effective in short distances along with being unique/personalizable and causing minimal harm to normal surrounding cells. Furthermore, radioligand binding can provide information about receptor-ligand interactions in vitro and in vivo. Choosing the right radioligand for the desired application is important. The radioligand must be radiochemically pure, stable, and demonstrate a high degree of selectivity, and high affinity for their target.
== History == thumb|Depiction of Wilhelm Roentgen observing an X-ray
Excerpted from Wikipedia’s “radioligand” article, available under the CC BY-SA 4.0 licence.